PP.07.09: EFFECT OF SINGLE TABLET OF FIXED-DOSE AMLODIPINE AND ATORVASTATIN ON BLOOD PRESSURE AND LIPID PROFILE IN YOUNG PATIENTS. (June 2015)

• Record Type: Journal Article
• Authors: Stancheva, N.; Yakova, D.; Chakalova, T.; Yanakieva, A.; Hristov, M.; Tisheva, S.N.
• Is Part Of: Journal of hypertension. Volume 33(2015)Supplement 1
• Publication Date: 2015-06
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000467922.85264.b3
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition. Data have shown that even relatively small reductions in both blood pressure and cholesterol levels can lead to large reductions in the risk for cardiovascular events. Furthermore, it is very important to treat young patients adequately in order to prevent cardiovascular complications. The objective of this study was to investigate the effects of a single pill of amlodipine (5 mg)/atorvastatin (10 mg) on blood pressure and lipid profile and adherence to medication in young hypertensive patients with dyslipidemia and no history of ischaemic heart disease. Design and method: This combination tablet was administered to 59 patients (36 males) with mean age 47 ± 2, 4 years, and blood pressure, lipid profile, renal/liver function were measured at baseline, 1, and 3 months. Medication adherence was examined using a questionnaire at 3 months. Results: LDL-Cholesterol, triglycerides and total cholesterol were significantly decreased at 1 and 3 months compared with baseline. Data shows that mean baseline office BP of 164/98mmHg reduced by 19/9 mmHg to 145/90 mmHg at 1 month, and to 139/88 at 3 months. Mean systolic pressure decreased significantly at 1 and 3 months. The results of the questionnaire showed that 94 % of patients were satisfied with this medication. No severe adverse events were observed. Conclusions: This combination tablet controlled both hypertension and dyslipidemia well in young patients. The control of two of the major cardiovascular risk factors might suggest the prevention of atherosclerosis by this medication. In addition, this medication is expected to improve medication adherence which is a very important prerequisite for successful treatment and prevention especially in young patients.